BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT02398929

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02398929
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Hong Kong SAR China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02398929. Allocation not applicable; no masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2021-01-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study)
Acronym
BRAVE
Condition
Hypertension
Intervention (Drug)
Bisoprolol 2.5 mg
Intervention (Drug)
Placebo
Lead sponsor
Chinese University of Hong Kong (class: other)

Record details

Record id
cardio:ct-nct02398929
Content hash
de96f55f955bb4140c7103c1f56dca8e7d4c279e3f5cc150e15b4a2aa290f1b2